Managing and Monitoring Infections and Neurological Toxicities in Patients Receiving Bispecific Therapies

EP: 1.John’s Journey with R/R MM

EP: 2.Patient Education: Preparing Patients for Bispecific Treatment in R/R MM

Now Viewing

EP: 3.Managing and Monitoring Infections and Neurological Toxicities in Patients Receiving Bispecific Therapies

EP: 4.Handling Dose Modifications and Treatment Interruptions Due to AEs With Bispecifics

EP: 5.Multidisciplinary Approaches to Managing AEs with Bispecifics

EP: 6.Eva’s Treatment Journey with R/R MM

EP: 7.Referring Patients on Bispecific Therapy: Initial Steps

EP: 8.Referral Process: Best Practices for Clear Communication

EP: 9.Referral Process With Bispecifics: Challenges and Support

Video content above is prompted by the following:

• How do you approach the prevention and management of infections in patients receiving bispecific therapies, particularly considering the unique target of talquetamab (GPRC5D)?
• What are your protocols for monitoring and managing neurological toxicities in patients receiving bispecific therapies?
  • Are there any specific considerations for talquetamab?